SequelSEC

Nautilus Biotechnology, Inc. NAUT

Laboratory Analytical Instruments · CIK 0001808805 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$190.00K
Fiscal year ended 2026-06-30
Operating income
Unavailable
Fiscal year ended 2026-06-30
Free cash flow
Unavailable
Fiscal year ended 2026-06-30

Nautilus Biotechnology, Inc. (NAUT) reported revenue of $190.00K and net income of -$14.47M for the fiscal year ended 2026-06-30. This page shows 2 annual periods of income statement, balance sheet and cash flow figures normalized from Nautilus Biotechnology, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Laboratory Analytical Instruments.

Income

Nautilus Biotechnology, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302025-06-30
Revenue$190.00K$0
Cost of revenue$15.00K$0
Gross profit$175.00K$0
Operating incomeUnavailableUnavailable
Net income-$14.47M-$15.03M
Research & development$9.61M$10.39M
Weighted-average diluted sharesshares 127.14Mshares 126.20M
Pretax incomeUnavailableUnavailable
Income tax expense$0$0
Diluted EPS$-0.11$-0.12
Selling, general & administrative$6.32M$6.70M
General & administrativeUnavailable$6.70M
Selling & marketingUnavailableUnavailable

Balance

Nautilus Biotechnology, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302025-06-30
Cash & equivalents$13.17M$34.46M
Total assets$163.58M$213.19M
Current assets$87.63M$150.72M
Total liabilities$32.46M$32.10M
Current liabilities$8.64M$8.14M
Total equity incl. NCI$131.11M$181.09M
Temporary (mezzanine) equityUnavailableUnavailable
Inventory$600.00KUnavailable
Accounts receivableUnavailableUnavailable
GoodwillUnavailableUnavailable
Long-term debtUnavailableUnavailable
Accounts payable$1.10M$974.00K

Cash flow

Nautilus Biotechnology, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302025-06-30
Operating cash flowUnavailableUnavailable
Capital expendituresUnavailableUnavailable
Investing cash flowUnavailableUnavailable
Financing cash flowUnavailableUnavailable
Net change in cashUnavailableUnavailable
Stock-based compensationUnavailableUnavailable
Common dividends paidUnavailableUnavailable
Common share repurchasesUnavailableUnavailable
Depreciation & amortizationUnavailableUnavailable

Derived

Nautilus Biotechnology, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302025-06-30
Free cash flowUnavailableUnavailable
Gross margin92.1%Unavailable
Operating marginUnavailableUnavailable
FCF marginUnavailableUnavailable
SBC / revenueUnavailableUnavailable
Current ratio10.14x18.52x
Revenue YoY growthUnavailableUnavailable
Net margin-7615.3%Unavailable
R&D / revenue5059.5%Unavailable
CapEx / revenueUnavailableUnavailable
Long-term debt / equityUnavailableUnavailable
Effective tax rateUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open NAUT in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-07-28View SEC filing
10-Q · Filed 2026-04-28View SEC filing
10-K · Filed 2026-02-26View SEC filing
10-Q · Filed 2025-10-28View SEC filing
10-Q · Filed 2025-07-31View SEC filing
10-Q · Filed 2025-04-29View SEC filing

Companies in the same industry

A ASTC AVTR BFNH BIO BNGO BRKR CTKB EYPT HBIO ILMN LCTC

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.